Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.56 |
| ▸ | F2R | P25116 | 10/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429918 | 0.88 | ITGB3 (0.72) | ITGB3ITGA2BF2RALDH1A1 | |
| SCHEMBL6538722 | 0.82 | HPGD (0.52) | MEN1KMT2AITGB3ITGA2BF2R | |
| SCHEMBL7501858 | 0.82 | HPGD (0.52) | MEN1KMT2AITGB3ITGA2BF2R | |
| SCHEMBL6538726 | 0.82 | HPGD (0.52) | MEN1KMT2AITGB3ITGA2BF2R | |
| SCHEMBL5517503 | 0.81 | HSD11B1 (0.70) | MEN1KMT2ATP53HSD11B1ALDH1A1 | |
| SCHEMBL22602813 | 0.81 | HSD11B1 (0.70) | MEN1KMT2ATP53HSD11B1ALDH1A1 | |
| SCHEMBL3952911 | 0.81 | HSD11B1 (0.70) | MEN1KMT2ATP53HSD11B1ALDH1A1 | |
| SCHEMBL3664951 | 0.81 | ALDH1A1 (0.50) | MEN1KMT2AITGB3ITGA2BF2R | |
| SCHEMBL25453023 | 0.80 | ALDH1A1 (0.66) | MEN1KMT2AHSD11B1ALDH1A1 | |
| SCHEMBL3455258 | 0.80 | ALDH1A1 (0.66) | MEN1KMT2AHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | THE ASAN FOUNDATION (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230129721-A1 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | THE ASAN FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | SERPINC1, F3, F11 | MEN1 16/4885KMT2A 2101/4885TP53 3544/4885 |
| US-20230129721-A1 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GC, ADORA2B, TBCB | MEN1 67/4885KMT2A 3950/4885TP53 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.